What do systematic reviews say?

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes overall survival (OS), measured by the number of deaths over time… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.43 [0.15, 1.21]
  2 studies · 171 participants
  Very low

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes adverse events, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 1.58
  2 studies · 162 participants
  Very low

Neoadjuvant treatment vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes time to recurrence (TTR),measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.51 [0.22, 1.17]
  2 studies · 171 participants
  Very low

Neoadjuvant treatment vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes overall survival (OS), measured by number of deaths over time,Median compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.28 [0.03, 2.25]
  1 study · 21 participants
  Very low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.02 [0, 0.22]
  1 study · 21 participants
  Very low